Explore

Trendline Trendline
ATB Therapeutics Appoints Mark Throsby as CEO to Lead Growth Phase

ATB Therapeutics Appoints Mark Throsby as CEO to Lead Growth Phase

ATB Therapeutics Appoints Mark Throsby as CEO to Lead Growth Phase
Trendline Trendline
Herantis Partners with Indivi for Digital Biomarker Integration in HER-096 Phase II Trial

Herantis Partners with Indivi for Digital Biomarker Integration in HER-096 Phase II Trial

Herantis Partners with Indivi for Digital Biomarker Integration in HER-096 Phase II Trial
Trendline Trendline
Turn Therapeutics to Present GX-03 at Jefferies Global Healthcare Conference

Turn Therapeutics to Present GX-03 at Jefferies Global Healthcare Conference

Turn Therapeutics to Present GX-03 at Jefferies Global Healthcare Conference
Trendline Trendline
Oligomerix Completes Phase 1a Study of Alzheimer's Drug OLX-07010, Showing Promise for Future Trials

Oligomerix Completes Phase 1a Study of Alzheimer's Drug OLX-07010, Showing Promise for Future Trials

Oligomerix Completes Phase 1a Study of Alzheimer's Drug OLX-07010, Showing Promise for Future Trials
Trendline Trendline
Passkey Therapeutics Appoints New CMO to Advance Drug Combination Platform

Passkey Therapeutics Appoints New CMO to Advance Drug Combination Platform

Passkey Therapeutics Appoints New CMO to Advance Drug Combination Platform
Trendline Trendline
Tiziana Life Sciences Reports Positive Data for Intranasal Foralumab in Multiple Sclerosis

Tiziana Life Sciences Reports Positive Data for Intranasal Foralumab in Multiple Sclerosis

Tiziana Life Sciences Reports Positive Data for Intranasal Foralumab in Multiple Sclerosis
Trendline Trendline
Atossa Therapeutics Highlights Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy

Atossa Therapeutics Highlights Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy

Atossa Therapeutics Highlights Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy
Trendline Trendline
Oligomerix Completes Phase 1a Study of Alzheimer's Drug OLX-07010, Showing Promising Safety Profile

Oligomerix Completes Phase 1a Study of Alzheimer's Drug OLX-07010, Showing Promising Safety Profile

Oligomerix Completes Phase 1a Study of Alzheimer's Drug OLX-07010, Showing Promising Safety Profile
Trendline Trendline
Tiziana Life Sciences Reports Positive Data for Intranasal Foralumab in Multiple Sclerosis Treatment

Tiziana Life Sciences Reports Positive Data for Intranasal Foralumab in Multiple Sclerosis Treatment

Tiziana Life Sciences Reports Positive Data for Intranasal Foralumab in Multiple Sclerosis Treatment
Trendline Trendline
Passkey Therapeutics Appoints New CMO to Lead Drug Combination Platform

Passkey Therapeutics Appoints New CMO to Lead Drug Combination Platform

Passkey Therapeutics Appoints New CMO to Lead Drug Combination Platform
Trendline Trendline
Regeneron and Parabilis Collaborate to Develop New Drug Class Targeting Undruggable Proteins

Regeneron and Parabilis Collaborate to Develop New Drug Class Targeting Undruggable Proteins

Regeneron and Parabilis Collaborate to Develop New Drug Class Targeting Undruggable Proteins
Trendline Trendline
FDA Alignment and AI Integration Critical for Rare Disease Drug Development

FDA Alignment and AI Integration Critical for Rare Disease Drug Development

FDA Alignment and AI Integration Critical for Rare Disease Drug Development